185 related articles for article (PubMed ID: 30816329)
1. BCL2 blockade overcomes MCL1 resistance in multiple myeloma.
Siu KT; Huang C; Panaroni C; Mukaihara K; Fulzele K; Soucy R; Thorburn C; Cidado J; Drew L; Chattopadhyay S; Raje N
Leukemia; 2019 Aug; 33(8):2098-2102. PubMed ID: 30816329
[No Abstract] [Full Text] [Related]
2. Targeting MCL1, Companies Aim to Unblock Apoptosis.
Cancer Discov; 2019 May; 9(5):572. PubMed ID: 30944116
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
Wong KY; Chim CS
J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
[TBL] [Abstract][Full Text] [Related]
4. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
5. Secondary plasma cell leukaemia treated with single agent venetoclax.
Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
[No Abstract] [Full Text] [Related]
6. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
[No Abstract] [Full Text] [Related]
7. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
Boiko S; Proia T; San Martin M; Gregory GP; Wu MM; Aryal N; Hattersley M; Shao W; Saeh JC; Fawell SE; Johnstone RW; Drew L; Cidado J
Blood; 2021 May; 137(21):2947-2957. PubMed ID: 33259592
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.
Bala Tannan N; Manzari MT; Herviou L; Da Silva Ferreira M; Hagen C; Kiguchi H; Manova-Todorova K; Seshan V; de Stanchina E; Heller DA; Younes A
Blood; 2021 Apr; 137(15):2057-2069. PubMed ID: 33067607
[TBL] [Abstract][Full Text] [Related]
9. Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH; Kaufman JL
Am J Hematol; 2021 Mar; 96(3):E68-E71. PubMed ID: 33275813
[No Abstract] [Full Text] [Related]
10. ABT-199 for chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
[No Abstract] [Full Text] [Related]
11. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax for the treatment of multiple myeloma.
Vaxman I; Sidiqi MH; Gertz M
Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
[No Abstract] [Full Text] [Related]
13. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
Jain P; Mims AS
Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
[No Abstract] [Full Text] [Related]
14. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Algarín EM; Díaz-Tejedor A; Mogollón P; Hernández-García S; Corchete LA; San-Segundo L; Martín-Sánchez M; González-Méndez L; Schoumacher M; Banquet S; Kraus-Berthier L; Kloos I; Derreal A; Halilovic E; Maacke H; Gutiérrez NC; Mateos MV; Paíno T; Garayoa M; Ocio EM
Haematologica; 2020 Mar; 105(3):e116-e120. PubMed ID: 31320555
[No Abstract] [Full Text] [Related]
15. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL; Boise LH
Leukemia; 2019 May; 33(5):1291-1296. PubMed ID: 30679802
[No Abstract] [Full Text] [Related]
16. Suzanne Cory: Life-and-Death Switches: the Rise of BH3 Mimetics.
Trends Cancer; 2016 Oct; 2(10):537-539. PubMed ID: 28741484
[No Abstract] [Full Text] [Related]
17. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.
Touzeau C; Ryan J; Guerriero J; Moreau P; Chonghaile TN; Le Gouill S; Richardson P; Anderson K; Amiot M; Letai A
Leukemia; 2016 Mar; 30(3):761-4. PubMed ID: 26174630
[No Abstract] [Full Text] [Related]
18. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
19. Pioneering apoptosis-targeted cancer drug poised for FDA approval.
Mullard A
Nat Rev Drug Discov; 2016 Mar; 15(3):147-9. PubMed ID: 26931080
[No Abstract] [Full Text] [Related]
20. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
Carter BZ; Tao W; Mak PY; Ostermann LB; Mak D; McGeehan G; Ordentlich P; Andreeff M
Blood; 2021 Oct; 138(17):1637-1641. PubMed ID: 34232981
[No Abstract] [Full Text] [Related]
[Next] [New Search]